Paradia, Dorotea C.
HRN: 03-48-74 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/13/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
02/13/2025
02/20/2025
IV
2.25G
Q8 X7days
CAP
Waiting Final Action
Indication: Empiric Type of Infection: PneumoniaSkin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes